MA34232B1 - Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation - Google Patents

Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation

Info

Publication number
MA34232B1
MA34232B1 MA35369A MA35369A MA34232B1 MA 34232 B1 MA34232 B1 MA 34232B1 MA 35369 A MA35369 A MA 35369A MA 35369 A MA35369 A MA 35369A MA 34232 B1 MA34232 B1 MA 34232B1
Authority
MA
Morocco
Prior art keywords
xanthine oxidase
statins
association
oxidase inhibitors
human
Prior art date
Application number
MA35369A
Other languages
English (en)
Inventor
Francesco Melani
Sandro Giuliani
Carlo Alberto Maggi
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42753376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34232(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of MA34232B1 publication Critical patent/MA34232B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention a pour objet l'association de principes actifs, c'est-à-dire d'un inhibiteur de la xanthine oxydase avec un ou plusieurs inhibiteurs de la HMG CoA réductase, des compositions pharmaceutiques comprenant lesdits principes actifs, destinée à être utilisée dans un traitement thérapeutique humain ou vétérinaire, et des procédés pour sa préparation.
MA35369A 2010-05-10 2011-05-06 Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation MA34232B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000231A IT1400310B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e statine e loro uso.
PCT/EP2011/057343 WO2011141387A1 (fr) 2010-05-10 2011-05-06 Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation

Publications (1)

Publication Number Publication Date
MA34232B1 true MA34232B1 (fr) 2013-05-02

Family

ID=42753376

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35369A MA34232B1 (fr) 2010-05-10 2011-05-06 Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation

Country Status (23)

Country Link
US (1) US20130116291A1 (fr)
EP (1) EP2568981A1 (fr)
JP (1) JP2013526499A (fr)
KR (1) KR20130079427A (fr)
CN (1) CN103025329A (fr)
AR (1) AR081375A1 (fr)
AU (1) AU2011252193A1 (fr)
BR (1) BR112012028892A2 (fr)
CA (1) CA2798707A1 (fr)
CL (1) CL2012003033A1 (fr)
CO (1) CO6630144A2 (fr)
CR (1) CR20120618A (fr)
EA (1) EA201201529A1 (fr)
IL (1) IL222926A0 (fr)
IT (1) IT1400310B1 (fr)
MA (1) MA34232B1 (fr)
MX (1) MX2012013052A (fr)
NZ (1) NZ603397A (fr)
PE (1) PE20130811A1 (fr)
SG (1) SG185445A1 (fr)
TW (1) TW201206430A (fr)
WO (1) WO2011141387A1 (fr)
ZA (1) ZA201209294B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112370473A (zh) * 2020-12-04 2021-02-19 首都医科大学附属北京朝阳医院 他汀组合物及其在制备治疗高尿酸血症药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2073981C (fr) 1990-11-30 2002-01-08 Shiro Kondo Derives de 2-arylthiazole et composition pharmaceutique a base de ces derives
PL200710B1 (pl) 1998-06-19 2009-01-30 Teijin Pharma Ltd Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2005027887A2 (fr) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Procedes et compositions permettant d'ameliorer la fonction endotheliale
CA2617248C (fr) 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methodes de traitement de l'hypertension
US20070208041A1 (en) * 2005-10-13 2007-09-06 Stamler Jonathan S Compositions for the treatment and prevention of heart disease and methods of using same
WO2007062028A2 (fr) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Traitement d'allongement de l'intervalle qt et maladies associees
WO2008064015A1 (fr) 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America Procédés pour préserver la fonction rénale au moyen d'inhibiteurs de xanthine oxydoréductase

Also Published As

Publication number Publication date
IT1400310B1 (it) 2013-05-24
IL222926A0 (en) 2012-12-31
TW201206430A (en) 2012-02-16
SG185445A1 (en) 2012-12-28
BR112012028892A2 (pt) 2016-07-26
CA2798707A1 (fr) 2011-11-17
CL2012003033A1 (es) 2013-06-21
JP2013526499A (ja) 2013-06-24
WO2011141387A1 (fr) 2011-11-17
ITRM20100231A1 (it) 2011-11-11
MX2012013052A (es) 2013-07-03
KR20130079427A (ko) 2013-07-10
AU2011252193A1 (en) 2012-11-29
EP2568981A1 (fr) 2013-03-20
CN103025329A (zh) 2013-04-03
US20130116291A1 (en) 2013-05-09
CO6630144A2 (es) 2013-03-01
NZ603397A (en) 2014-03-28
EA201201529A1 (ru) 2013-04-30
CR20120618A (es) 2014-03-21
ZA201209294B (en) 2013-08-28
AR081375A1 (es) 2012-08-29
PE20130811A1 (es) 2013-08-08

Similar Documents

Publication Publication Date Title
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
MA34002B1 (fr) Thérapie antivirale
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
NO20073601L (no) Immunresponsmodifikator-skumformuleringer
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
TW200626156A (en) Amido compounds and their use as pharmaceuticals
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA41654B2 (fr) Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
MA38699B1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
MA34106B1 (fr) Combinaison de composés organiques
White et al. Effects of naproxcinod on blood pressure in patients with osteoarthritis
MA34232B1 (fr) Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation
MA34297B1 (fr) Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation